A commenter expressed concern that including spending on necessary services in EBCMs could inadvertently reward clinicians for reducing spending on essential care, potentially leading to worse patient outcomes that may not be reflected in quality measures, noting that average spending on patients could increase due to factors outside a clinician's control, such as rising drug prices or services ordered by other physicians, which could unfairly penalize clinicians
Post-Therapy Monitoring & Wellness Coaching
doi: 10.1016/j.microb.2025.100497 579 MaorMLevy BarazanyHKolodkin-GalI
Side effect profiles remain comparable, with Tirzepatide showing slightly lower nausea rates (25%) versus Retatrutide (28%)
Lazarus Labs supplies Melanotan II in Australia as a 10 mg lyophilised reference material at 99 % purity, with a certificate of analysis for every lot
Both medications are relatively new, meaning they are still protected by patents